Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 405

Sort by

Sort Order Select

Journal Articles

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Blood (2025) 146 (24): 2902–2913.

https://doi.org/10.1182/blood.2025029360

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

María-Jesús Blanchard, Marcos Lorenzo Perez, Ana Saus Carreres, Mario Arnao, Elena Fernández Poveda, Ana Pilar Gonzalez, Sunil Lakhwani, Juan Luis Reguera, Jose Maria Sanchez Pina, Ana Sánchez Quintana, Miriam Concepcion Gonzalez Pardo, María-Victoria Mateos, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 2272.

https://doi.org/10.1182/blood-2025-2272

Published: 2025

Journal Articles

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Enrique Ocio, Aurore Perrot, Jesus San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Sara Bringhen, Paula Rodriguez-Otero, Mohamad Mohty, Robert Orlowski, Meletios Dimopoulos, Xavier Leleu, María-Victoria Mateos, Philippe Moreau, Sandrine Macé, Ecrem Kodas, Christine Tekle, Umer Khan, Corina Oprea, Thierry Facon

Blood (2025) 146 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2025-2267

Published: 2025

Journal Articles

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

Blood (2025) 146 (Supplement 1): 2265.

https://doi.org/10.1182/blood-2025-2265

Published: 2025

Journal Articles

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study

Blood (2025) 146 (Supplement 1): 2264.

https://doi.org/10.1182/blood-2025-2264

Published: 2025

Journal Articles

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Blood (2025) 146 (Supplement 1): 372.

https://doi.org/10.1182/blood-2025-372

Published: 2025

Journal Articles

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Blood (2025) 146 (Supplement 1): 371.

https://doi.org/10.1182/blood-2025-371

Published: 2025

Journal Articles

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Blood (2025) 146 (Supplement 1): 366.

https://doi.org/10.1182/blood-2025-366

Published: 2025

Journal Articles

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis-Pistofidis, Febe Smits, Carmen Roncal, Michelle Aranha, David Zihala, Michaela Machu, Nikolaos Tsakirakis, Panagiotis Bakouros, Ourania Tsitsilonis, Eirini Solia, Cristina Moreno, Catarina Maia, Esperanza Martin-Sanchez, José J. Perez, Cristina Encinas, Rafael Rios Tamayo, Albert Oriol, María-Jesús Blanchard, Felipe de Arriba, Esther González García, Sunil Lakhwani, Anna Sureda Balarí, Valentin Cabanas Perianes, Fernando Escalante Barrigón, Estrella Carrillo-Cruz, Albert Pérez-Montaña, Enrique Ocio, Joan Bargay, Alberto Orfao, Tomas Jelinek, Irene Ghobrial, Tuna Mutis, Sonja Zweegman, Evangelos Terpos, Efstathios Kastritis, Joaquin Martinez-Lopez, Juan-Jose Lahuerta Palacios, Carlos Fernandez de Larrea, Laura Rosiñol, Joan Batista Blade Creixenti, Paula Rodriguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Maria Teresa Cedena Romero, Noemí Puig, Bruno Paiva

Blood (2025) 146 (Supplement 1): 365.

https://doi.org/10.1182/blood-2025-365

Published: 2025

Journal Articles

Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Heinz Ludwig, Evangelos Terpos, Mario Boccadoro, Sara Martinez, Carmen Kahatt, Javier Jimenez Jimenez, Antonio Nieto, Sonia Extremera, Javier Gomez, Vicente Alfaro, Ruthanna Davi, Xiang Yin, María-Victoria Mateos

Blood (2025) 146 (Supplement 1): 7558.

https://doi.org/10.1182/blood-2025-7558

Published: 2025

Journal Articles

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Blood (2025) 146 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2025-2288

Published: 2025

Journal Articles

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Blood (2025) 146 (Supplement 1): 496.

https://doi.org/10.1182/blood-2025-496

Published: 2025

Journal Articles

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Blood (2025) 146 (Supplement 1): 494.

https://doi.org/10.1182/blood-2025-494

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Blood (2025) 146 (Supplement 1): 493.

https://doi.org/10.1182/blood-2025-493

Published: 2025

Journal Articles

Talquetamab outcomes from practice outside of clinical trials: The bital study

María-Victoria Mateos, Marcos Lorenzo Perez, Ana Saus Carreres, Mario Arnao, Elena Fernández Poveda, Ana Pilar Gonzalez, Sunil Lakhwani, Juan Luis Reguera, Jose Maria Sanchez Pina, Ana Sánchez Quintana, Miriam Concepcion Gonzalez Pardo, María-Jesús Blanchard, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 5827.

https://doi.org/10.1182/blood-2025-5827

Published: 2025

Journal Articles

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

Suzanne Trudel, Vania Hungria, María-Victoria Mateos, Chee Paul Lin, Julie Byrne, James Parker, Molly Purser, Sandhya Sapra, Farrah Pompilus, Sumita Roy-Ghanta, Giulia Fulci, Joanna Opalinska, Neal Sule, Brandon Kremer, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 5823.

https://doi.org/10.1182/blood-2025-5823

Published: 2025

Journal Articles

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Blood (2025) 146 (Supplement 1): 5820.

https://doi.org/10.1182/blood-2025-5820

Published: 2025

Journal Articles

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Blood (2025) 146 (Supplement 1): 2238.

https://doi.org/10.1182/blood-2025-2238

Published: 2025

Journal Articles

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 250.

https://doi.org/10.1182/blood-2025-250

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Talquetamab outcomes from practice outside of clinical trials: The bital study

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only